HeartFlow: combating heart disease with AI-generated models
Claire Shaw – Portfolio Director
- Heart disease is the number one cause of death globally
- Medical technology company HeartFlow is revolutionising heart disease diagnosis with artificial intelligence (AI)
- Its non-invasive cardiac tests address a large untapped market and are more cost-effective and accurate than existing diagnostic tools
Heart disease is responsible for 16 per cent of deaths worldwide or about nine million lives each year. Traditional methods of diagnosis can involve multiple tests, false negative results and some patient risks.
So what if there was a safer, cheaper, and more effective way to diagnose it?
This graphic from Scottish Mortgage Investment Trust shows how one of its portfolio companies, HeartFlow, uses artificial intelligence (AI) to diagnose heart disease effectively.
What is heart disease?
To understand the technology, it’s helpful to start with a definition of heart disease. Ischaemic heart disease, also known as coronary artery disease, is the most common type of heart disease.
It is caused by plaque buildup inside the blood vessels that limits blood supply and may cause heart pain, heart attacks or heart failure.
Traditionally, doctors have diagnosed heart disease in a few ways. Stress tests monitor heart activity under exercise or medication-induced stress. However, they can have downsides such as false negative results, additional required testing or high radiation exposure.
Computerised tomography (CT) scans use X-rays to view blood vessel narrowing but they do not indicate whether the blood flow is impacted.
Finally, invasive coronary angiograms take X-rays of the heart’s arteries while a catheter is inserted into the groin or wrist and threaded up to the heart. Unfortunately, this invasive test is often unnecessary, as more than half of patients who undergo the test do not have coronary artery disease.
Measuring coronary artery blood flow
Medical technology company HeartFlow has a different approach. Using CT scans and artificial intelligence, HeartFlow can create a 3D, colour-coded model of the heart. Doctors can easily see where coronary arteries are narrowing and where the blood flow to the heart is reduced.
The model also assigns a numerical value to each artery so doctors can see the extent of blood flow reduction.
| Value | Meaning |
| 1.0 | Full blood flow |
| 0.8 – 1.0 | Stent not required |
| 0.75 - 0.8 | Other clinical info required |
| 0.75 and below | May benefit from stent |
Using this information, the doctor can create an informed treatment plan for the patient. For instance, the doctor may recommend a stent, a small wire mesh tube that helps keep a narrowed artery open.
Revolutionising heart care
HeartFlow’s innovative heart models have many benefits over traditional testing. For example, they are:
- Twice as likely to identify heart disease
- Offer 26 per cent cost savings per patient
- Result in an 83 per cent reduction of unnecessary coronary angiograms
HeartFlow’s models are convenient for doctors, too, with an average turnaround time of less than five hours, no upfront capital costs and seamless integration with existing hospital IT systems.
Along with being transformational for patients and doctors, Scottish Mortgage sees HeartFlow as an exciting investment opportunity. The company represents:
- A large market: Despite receiving relatively low media coverage, heart disease is the leading cause of death worldwide
- Proven success: HeartFlow is used at 40 of the top 50 US heart hospitals and has served more than 170,000 patients
- Room for growth: HeartFlow’s relatively new technology is used for less than 5 per cent of all cardiac testing that takes place today
- Geographic prospects: More hospitals could start using HeartFlow where it is commercially available in the US, Canada, Japan and Europe
- Constant innovation: The company holds 400 patents worldwide and is researching how its software could be used in other applications, such as preventative screening or heart transplants
Half of those with coronary artery disease die undiagnosed. HeartFlow’s non-invasive personalised cardiac test is a significant improvement over the existing diagnostic tools, in terms of its costs and effectiveness. With a large opportunity and the ambition to capitalise on it, the company is leading the way in helping healthcare systems develop affordable preventative screening regimes.
About the author - Claire Shaw
Portfolio Director
Claire Shaw is a portfolio director and plays a prominent role in servicing Scottish Mortgage’s UK shareholder base. Before joining in 2019, she spent over a decade as a fund manager with a focus on managing European equity portfolios for a global client base. With a background in analysing companies and communicating investment ideas, Claire is also responsible for creating engaging content that makes the Scottish Mortgage portfolio accessible to all its shareholders. Beyond that, she works closely with the managers, meeting with portfolio companies and conducting in-depth portfolio discussions with shareholders.
Regulatory Information
This content was produced and approved at the time stated and may not have been updated subsequently. It represents views held at the time of production and may not reflect current thinking. Read our Legal and regulatory information for further details.
A Key Information Document is available by visiting our Documents page. Any images used in this content are for illustrative purposes only.
This content does not constitute, and is not subject to the protections afforded to, independent research. Baillie Gifford and its staff may have dealt in the investments concerned. The views expressed are not statements of fact and should not be considered as advice or a recommendation to buy, sell or hold a particular investment.
Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). The investment trusts managed by Baillie Gifford & Co Limited are listed on the London Stock Exchange and are not authorised or regulated by the FCA.
Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 (BGA) holds a Type 1 licence from the Securities and Futures Commission of Hong Kong to market and distribute Baillie Gifford’s range of collective investment schemes and closed-ended funds such as investment trusts to professional investors in Hong Kong.
Baillie Gifford Asia (Singapore) Private Limited (BGAS) is regulated by the Monetary Authority of Singapore as a holder of a capital markets services licence to conduct fund management activities for institutional investors and accredited investors in Singapore. BGA and BGAS are wholly owned subsidiaries of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co.
Europe
Scottish Mortgage Investment Trust PLC (the “Company”) is an alternative investment fund for the purpose of Directive 2011/61/EU (the “AIFM Directive”). Baillie Gifford & Co Limited is the alternative investment fund manager (“AIFM”) of the Company and has been authorised for marketing to Professional Investors in this jurisdiction.
This content is made available by Baillie Gifford Investment Management (Europe) Limited (“BGE”), which has been engaged by the AIFM to carry out promotional activities relating to the Company. BGE is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. BGE also has regulatory permissions to perform promotional, advisory and Individual Portfolio Management activities. BGE has passported its authorisations under the mechanisms set out in the AIFM Directive.
Belgium
The Company has not been and will not be registered with the Belgian Financial Services and Markets Authority (Autoriteit voor Financiële Diensten en Markten / Autorité des services et marchés financiers) (the FSMA) as a public foreign alternative collective investment scheme under Article 259 of the Belgian Law of 19 April 2014 on alternative collective investment institutions and their managers (the Law of 19 April 2014). The shares in the Company will be marketed in Belgium to professional investors within the meaning the Law of 19 April 2014 only. Any offering material relating to the offering has not been, and will not be, approved by the FSMA pursuant to the Belgian laws and regulations applicable to the public offering of securities. Accordingly, this offering as well as any documents and materials relating to the offering may not be advertised, offered or distributed in any other way, directly or indirectly, to any other person located and/or resident in Belgium other than to professional investors within the meaning the Law of 19 April 2014 and in circumstances which do not constitute an offer to the public pursuant to the Law of 19 April 2014. The shares offered by the Company shall not, whether directly or indirectly, be marketed, offered, sold, transferred or delivered in Belgium to any individual or legal entity other than to professional investors within the meaning the Law of 19 April 2014 or than to investors having a minimum investment of at least EUR 250,000 per investor.
Germany
The Trust has not offered or placed and will not offer or place or sell, directly or indirectly, units/shares to retail investors or semi-professional investors in Germany, i.e. investors which do not qualify as professional investors as defined in sec. 1 (19) no. 32 German Investment Code (Kapitalanlagegesetzbuch – KAGB) and has not distributed and will not distribute or cause to be distributed to such retail or semi-professional investor in Germany, this document or any other offering material relating to the units/shares of the Trust and that such offers, placements, sales and distributions have been and will be made in Germany only to professional investors within the meaning of sec. 1 (19) no. 32 German Investment Code (Kapitalanlagegesetzbuch – KAGB).
Luxembourg
Units/shares/interests of the Trust may only be offered or sold in the Grand Duchy of Luxembourg (Luxembourg) to professional investors within the meaning of Luxembourg act by the act of 12 July 2013 on alternative investment fund managers (the AIFM Act). This document does not constitute an offer, an invitation or a solicitation for any investment or subscription for the units/shares/interests of the Trust by retail investors in Luxembourg. Any person who is in possession of this document is hereby notified that no action has or will be taken that would allow a direct or indirect offering or placement of the units/shares/interests of the Trust to retail investors in Luxembourg.
Switzerland
The Trust has not been approved by the Swiss Financial Market Supervisory Authority (“FINMA”) for offering to non-qualified investors pursuant to Art. 120 para. 1 of the Swiss Federal Act on Collective Investment Schemes of 23 June 2006, as amended (“CISA”). Accordingly, the interests in the Trust may only be offered or advertised, and this document may only be made available, in Switzerland to qualified investors within the meaning of CISA. Investors in the Trust do not benefit from the specific investor protection provided by CISA and the supervision by the FINMA in connection with the approval for offering.
Singapore
This content has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this content and any other content or material in connection with the offer or sale, or invitation for subscription or purchase, of the Trust may not be circulated or distributed, nor may be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act 2001, as modified or amended from time to time (SFA)) pursuant to Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
Where the Trust is subscribed or purchased under Section 275 by a relevant person which is:
(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section 275 except:
(1) to an institutional investor or to a relevant person or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(c)(ii) of the SFA,
(2) where no consideration is or will be given for the transfer;
(3) where the transfer is by operation of law; or
(4) pursuant to Section 276(7) of the SFA or Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.
